Company Research Report: Bluejay Diagnostics, Inc.

Company Overview

• Name: Bluejay Diagnostics, Inc.

• Mission: Focused on improving patient outcomes through cost-efficient, rapid, near-patient products for triage, diagnosis, and monitoring of disease progression.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Neil Dey: President, Chief Executive Officer, and Director

• Jason Cook: Chief Technology Officer

• Les DeLuca: VP of Operations

• Diane Palermo: Quality Assurance Manager

• Amit K. Roy: Principal Scientist

• Lekha Papammagari: Staff Scientist

• Randy Chin: Senior Engineer

• Jiansheng "Jason" Ouyang: Senior Systems Engineer

• Tina McCarthy: Clinical Trial Coordinator

• Tara Vaccarello: Operations Manager

• Headquarters: 360 Massachusetts Avenue, Suite 203, Acton, MA 01720

• Number of Employees: No information is available.

• Revenue: No information is available.

• What is the Company Known for: Developing easy-to-use, near-patient medical diagnostics tests.

Products

Symphony™

• Product Overview: Symphony is a near-patient biomarker detection platform aimed at improving healthcare outcomes by providing quantitative clinical chemistry results vital for triage and acute care.

• High-Level Description:

• Implements reliable ELISA methodology with advancements in nanotechnology.

• Features microfluidics and interrupted fluid dynamics for fast, simple, safe, and highly sensitive biomarker detection.

• Key Features:

• Automated diagnostic system.

• Includes a fluorescence immuno-analyzer using a single-use diagnostic test cartridge.

• Features a 'sample-to-result' format reducing the need for technician intervention.

• Simplifies infrastructure allowing testing in traditionally non-feasible locations with low cost and rapid outcome.

• Technology Platform:

• Uses intermitted centrifugation and precision microchannel technology.

• Needs only three drops of blood for obtaining test results in 20 minutes.

• Single-use cartridges contain reagents, reducing clean-up time and maintenance.

• Specific antibodies enable highly sensitive and specific results.

Recent Developments

1. New Product Launches & Features:

• No new product launches have been reported.

• Completion of planned clinical studies for the Symphony IL-6 Test.

2. Partnerships and Agreements:

• Signed a collaboration agreement with Blood Centers of America to develop commercial relationships utilizing the Symphony platform in blood and hospital markets.

3. Regulatory and Financial Developments:

• Reports FDA agreed to consider the plan for a De Novo submission for the Symphony IL-6 Test.

• Financial Results for the quarter ended March 31, 2022, and June 30, 2022.

Contact

• Address: 360 Massachusetts Avenue, Suite 203, Acton, MA 01720

• Phone: 844.327.7078 / 978.631.4884

• Email: contact@bluejaydx.com

Note: For further inquiries or detailed discussions, reach out via the contact information provided or consult the company's newsroom and investor relations sections for updated press releases and reports.

---

This report presents the currently available, structured, comprehensive data on Bluejay Diagnostics, Inc., focusing strongly on company operations and its technological advancements.